Methods: Multivariable analyses of the final dataset from the ABC-02 study were carried out. All variables were simultaneously included in a Cox proportional hazards model, and backward elimination was used to produce the final model (using a significance level of 10%), in which the selected variables were associated independently with outcome. This score was validated externally by receiver operating curve (ROC) analysis using the independent international dataset.
introduction Biliary tract cancer is an uncommon cancer in developed countries with ∼1500 new cases in the UK and 9000 new cases in the United States per year although the incidence is increasing [1] (http://www.cancerresearchuk.org/cancer-info/cancerstats/). Most patients are inoperable at presentation and the majority relapse following surgery; therefore, therapy is mainly palliative. The National Cancer Research Institute (UK) ABC-02 study demonstrated a survival advantage for patients receiving cisplatin and gemcitabine (CisGem) compared with gemcitabine alone and this combination has become the international standard of care in advanced disease [2] .
In a preliminary analysis of prognostic factors in ABC-02, a multivariable analysis across 16 variables suggested that Eastern Cooperative Oncology Group performance status (ECOG PS) and the presence of metastatic disease were significant prognostic indicators of progression-free survival (PFS) and overall survival (OS), as were neutrophilia and anaemia [3] . Notably, the location of the tumour within the biliary tract (cholangiocarcinoma, gall-bladder or ampulla of Vater) did not appear to influence outcome. Miyakawa et al. evaluated a surgical series of 5584 patients [4] and demonstrated a trend for improved survival in ampullary cancers compared with bile duct and gallbladder cancers. In patients with advanced disease, the neutrophil lymphocyte ratio [5] , ECOG PS [6] , PFS after first-line chemotherapy of >6 months [6] , previous surgery on the primary tumour [6] , primary tumour location [7] , and the number of sites of advanced disease [7] have been considered prognostic factors.
We present multivariable analyses from the ABC-02 study and validate proposed prognostic factors with a dataset of 10 studies in advanced biliary tract cancer (ABC) [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . The objective was to define potentially new prognostic factors for ABC to add to the evidence established by previous contributors [5] [6] [7] . This manuscript is consequent on a collaboration of the International Biliary Tract Cancer Collaborators.
methods
We investigated several baseline characteristics: age, sex, metastatic status, site of primary (bile duct, gall-bladder, or ampulla), type of tumour (adenocarcinoma versus other), ECOG PS, previous therapy, white blood cell (WBC) count (×10 9 /l), platelets (×10 9 /l), haemoglobin (g/dl), neutrophils (×10 9 /l), and bilirubin (µmol/l). All blood values were analysed as continuous variables.
The main analysis on the ABC-02 trial included all 410 patients. A secondary analysis was done by restricting ABC-02 dataset to 177 patients who received cisplatin plus gemcitabine and who had baseline ECOG PS 0 or 1, because this is the standard treatment for ABC and preliminary data from ABC-02 suggested patients with ECOG PS 0-1 benefit more from the addition of cisplatin to gemcitabine [3] .
Initial screening of the entire set of candidate baseline covariates was done by evaluating the prognostic performance of each variable among patients in ABC-02. This was investigated by calculating the true-positive rate (TPR) and the false-positive rate (FPR). TPR was defined as the percentage of patients with an event of interest that had a certain variable or had a value of a certain variable above a specific cut-off and FPR is the percentage of patients without an event of interest who had a certain variable or had a value of a certain variable above a specific cut-off. The likelihood ratio (LR) test [calculated as a ratio (TPR/FPR), therefore the higher the LR, the stronger the prognostic performance of a specific factor]. The prognostic performance of each baseline variable was examined on its own according to the following events of interest: having a PFS event within 6 months of randomization and death within 1 year from randomization.
All baseline variables were simultaneously included in a Cox proportional hazards model, and backward elimination was used to produce the final model (using a significance level of 0.10), in which the selected variables were associated independently with outcome (each had a P value of <0.10 after adjustment for the other factors in the model). A prognostic score was then generated from the linear predictor of the variables from the final Cox model [using the hazard ratio (HR) estimate for each factor]. This analysis was implemented for PFS (time from randomization to progression or death, whichever happened first) and OS (time from randomization to death). This score was validated externally using a dataset composed of 10 independent international datasets. For each patient in the validation dataset, the prognostic score was obtained and patients were classified by the event of interest. Prognostic test performance was examined by calculating the TPR and LR at fixed FPR values, and also by using receiver operating curves (ROCs). Prognostic performance was also investigated by assessing the association between prognostic scores and outcome of interest.
The Cox models derived using all patients in ABC-02 and the models including patients with ECOG PS 0 and 1 who received CisGem were also validated using each individual independent dataset separately as a validation dataset. A further sub-analysis was also carried out to assess the value of a derived neutrophil lymphocyte ratio (dNLR) as a prognostic factor in the context of the Cox models because this variable has been shown to be prognostic and potentially predictive of treatment benefit. [5, 18] The models derived from the backward selection were fitted without the variable neutrophils and using the variable dNLR instead. To assess the prognostic performance of such models, the linear predictor generated from these models was then applied to the external dataset as described above; dNLR was calculated as neutrophils/(WBC − neutrophils). The Stata version 12 statistical software package (Stata Corporation, College Station, TX) was used to analyse the data. results description of the training and validation datasets ABC-02 included 410 patients; of those, 204 patients received CisGem chemotherapy. The validation dataset included 753 patients and of those there were 394 PFS events at 6 months since randomization and 440 deaths at 1 year since randomization. A total of 5 patients were followed up for <6 months and did not have a PFS event and 17 patients were followed up for <12 months and did not die.
Supplementary Appendix Table S1 , available at Annals of Oncology online, summarizes each of the 10 different validation datasets. The medians and percentages of the key relevant factors considered in this analysis were similar in the training and validation datasets ( Table 1) . The median survival time in the entire ABC-02 cohort was slightly less than in the validation dataset (9.3 versus 10.0 months) and the percentage of deaths slightly higher (96% versus 88%). prognostic performance of individual baseline characteristics in ABC-02 Table 2 provides data on the prognostic performance of each baseline characteristic separately. The best factor for 1-year death is an ECOG PS of 2 which had a TPR of 17%, an FPR of 5%, and an LR of 3.4 (among patients who died within 1 year, the proportion of those with ECOG PS = 2 was 3.4 times greater than among those who did not die within 1 year). The best factor for the 6-month PFS was also ECOG PS 2 (TPR of 16%, FPR of 9%, and LR of 1.78). None of the other factors presented a TPR considerably higher than the FPR.
prognostic model from ABC-02 
assessment of prognostic performance of ABC-02 models
The prognostic performance using the above factors selected by Cox regression modelling is provided in supplementary Appendix Table S4 , available at Annals of Oncology online, and in Figure 1A and B. The ROC curves and the LR for values of the prognostic score for 6-month PFS and 1-year OS do not suggest a particularly good performance because the TPRs are close to the FPRs, and all LR values are below the recommended level of 10 for a strong prognosis. The area under the curve (AUC) ROC curves were modest [6-month PFS: 62% (95% CI 57-68), 1-year OS: 64% (95% CI 58-69), Supplementary Appendix Figure S1A and B, available at Annals of Oncology online]. Although the results of the ROC analysis show the models are of a limited use as a prognostic marker in a clinical setting, the Kaplan-Meier plots (supplementary Appendix Figure S2A and B, available at Annals of Oncology online) show an association between risk scores and OS/PFS. The 12-month survival rate for the low-score group was 51% (95% CI 42-59) compared with 22% (95% CI 15-29) for the high-score group (supplementary Appendix Table S5 , available at Annals of Oncology online). Similar findings were obtained when the models restricted to patients treated with CisGem who were ECOG PS 0 and 1 were applied to the validation dataset (supplementary Appendix Figure S3A and B, available at Annals of Oncology online). The assessment of the prognostic performance of the ABC-02 models using each external dataset in turn (supplementary Appendix Table S3 , available at Annals of Oncology online) suggested that the prognostic performance result obtained is dependent on the dataset used, with the highest ROC area obtained for the OS model derived from the patients receiving The TPR indicates the percentage of patients with an event, with the given characteristic; the FPR is the percentage of patients without an event, with the given characteristic; and the LR is calculated as TPR/FPR, indicating the strength of the prognostic factor. FPR, false-positive rate; LR, likelihood ratio; TPR, true-positive rate; WBC, white blood cells. [16] . The use of dNLR [19] instead of WBC and neutrophils does not improve the level AUC obtained. The AUC for OS models using dNLR was 63% (95% CI 57% to 70%) and for PFS models was 63% (95% CI 57% to 68%) and this is very similar to the results reported in Figure 1A and B (which relates to the use of WBC and neutrophils in the model).
discussion
The ABC-02 study established the standard of care for ABC and a set of clinically plausible prognostic factors were assembled from ABC-02 and validated in a similar population of patients with ABC in this study. The current analysis supports previous evidence that a prognostic model of neutrophils, disease status, bilirubin, ECOG PS, haemoglobin, WBC, and gender are prognostic factors for PFS and OS whereas age, bile duct or ampulla localization, type of tumour, previous therapy, and platelets were not. Although the model seems sensible to clinicians, our findings suggest the model generated from ABC-02 had limited prognostic value, falling short of the recommended level of LR >10 [20] .
Our study agrees with previous investigators [5] who suggested that neutrophils and disease status are important risk factors for PFS and OS. We found no evidence that any localization was prognostic in contrast to Peixoto et al. [7] . Our model had modest prognostic value, the strongest factor being ECOG PS. In a parallel analysis of ABC-02, Grenader et al. suggested that the dNLR was more predictive of outcome than ECOG PS, perhaps reflecting the inaccuracy of a clinical ECOG PS in estimating the biological impact of a large disease burden [18] . Interestingly, in our data, the NLR was not found to be a more accurate prognostic factor than WBC as has been previously suggested [5] . More accurate tools to assess ECOG PS, particularly in the elderly appear to improve our ability for estimation in cancer patients [21] . Interest in inflammation influencing cancer outcome is increasing, in part because of the potential impact of the Glasgow Prognostic Score, based primarily on C-reactive protein and albumin [22] . These data have stimulated research to elucidate a mechanism to link inflammation and malignancy, already established in part for ABC [23] . They also have potential implications for therapy, described in pancreatic cancer for ruxolitinib [24] as well as the increasing impact of programmed cell death 1 receptor inhibition in cancer therapy [25] .
Clinical criteria have formed the basis for our evaluation of prognosis but, increasingly, we should be linking these to genotype. Multiple novel technologies have proposed not only prognostic groups but also targetable genetic abnormalities in ABC [26] . Similarly, markers of resistance to chemotherapy [27] and the applicability of hENT-1 data for gemcitabine [28] in ABC may define better which patients to treat. We anticipate that ultimately prognostic factors will become closely linked with targetable genotype in order to present all management options for patients with ABC. The limitations of this study include the incomplete data and different treatment regimen in the validation dataset. This is reflected when the studies are inspected individually (supplementary Appendix Table S3 , available at Annals of Oncology online); however, when the datasets are combined, there are few differences between ABC-02 and the external dataset (Table 3) . Validation methodologies using external datasets are uncommon, so this is a strength in our study as we considered internal validation methodologies not sufficiently credible. The strengths of the data are derived from the quality of the outcome data of patients included in clinical studies and the size of the sample in a rare disease group.
In conclusion, although the predictive value of the models generated from ABC-02 and validated in an international dataset was limited, the factors included form the basis for potential stratification in ongoing studies. Clinicians may consider these data helpful in guiding practice without defining the standard of care.
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